Intelligence · Patents
Patents expiring in 2044
Annual patent cliff calendar for 2044 — US pharmaceutical patents by expiration date.
- Patents
- 1,766
Quick answer
1,766 indexed pharmaceutical patents have expiration dates in 2044. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 11866439
Ion channel modulators
granted -
US 11866491
Antibody for binding to interleukin 4 receptor
granted -
US 11865098
Methods and compositions for treating excessive sleepiness
granted -
US 11866794
Cas-ready mouse embryonic stem cells and mice and uses thereof
granted -
US 11865126
Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
granted -
US 11865174
Universal vaccine platform
granted -
US 11865111
Antiviral drugs targeting the N-terminal domain (NTD) of the coronavirus spike receptor binding domain (RBD)
granted -
US 11865157
Compositions and methods of targeting cancer stem cells
granted -
US 11866503
Methods for treating inflammatory conditions of the airway or lungs by administering antagonist monoclonal antibodies to interleukin-33 and interleukin-4 receptor
granted -
US 11866710
Transmembrane protease, serine 6 (TMPRSS6) iRNA compositions and methods of use thereof
granted -
US 11866442
Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
granted -
US 11866507
Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same
granted -
US 11866418
Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors
granted -
US 11865155
Plant extract obtained from Morus plant leaves which has an IC50 value to inhibit a-glucosidase I at a concentration of less than 90 uG/ml, compositions containing same, method of extraction and uses thereof
granted -
US 11865288
Devices for applying a topical treatment
granted -
US 11866727
Materials and methods for treatment of glycogen storage disease type 1A
granted -
US 11865140
Restimulation of cryopreserved tumor infiltrating lymphocytes
granted -
US 11865286
Active agent delivery devices and methods of using the same
granted -
US 11866446
Inhibitors of APOL1 and methods of using same
granted -
US 11866444
Oxabicycloheptane prodrugs
granted -
US 11866742
Fusion proteins comprising enzyme replacement therapy enzymes
granted -
US 11867695
Compositions and methods for detecting protease activity in biological systems
granted -
US 11865148
Methods of delivering transgenes to the eye
granted -
US 11866709
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
granted -
US 11865117
Pharmaceutical compositions comprising meloxicam
granted -
US 11866515
Hemiasterlin derivatives for conjugation and therapy
granted -
US 11865143
Bioeffective krill oil compositions
granted -
US 11866688
Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
granted -
US 11865134
Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (ANGPTL7) inhibitors
granted -
US 11865145
Compositions and methods for maintaining and restoring a healthy gut barrier
granted -
US 11866450
Modulators of Cystic Fibrosis Transmembrane Conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators
granted -
US 11865172
Materials and methods for respiratory disease control in canines
granted -
US 11865166
Nucleic acid encoding optimized immunogenic peptide that targets follicle stimulating hormone receptor
granted -
US 11866476
Masked IL-2-Fc fusion polypeptides
granted -
US 11866407
Compositions and methods for inhibiting Mpro and PLpro protease activity and for preventing and treating SARS-CoV-2 infection
granted -
US 11866747
Engineered meganucleases that target human mitochondrial genomes
granted -
US 11865171
Foot-and-mouth disease vaccine
granted -
US 11865125
APKC inhibitors and methods of treating a neurodegenerative disease or disorder
granted -
US 11865186
Gene therapy treatment of atrial fibrillation
granted -
US 11866743
Pharmaceutical formulations, methods for treating chemical warfare agent exposure, and modified biomolecules
granted -
US 11865122
Estrogen therapy for brain gray matter atrophy and associated disability
granted -
US 11865179
Progesterone formulations having a desirable PK profile
granted -
US 11866502
Anti-FGFR2 antibodies and methods of use thereof
granted -
US 11866488
Compositions comprising an anti-metallothionein antibody and a pancreatic cell targeting moiety
granted -
US 11866411
Therapeutic compounds and compositions
granted -
US 11865168
Compositions and methods for treating bacterial infections
granted -
US 11866518
Bicyclic peptide ligands specific for TSLP
granted -
US 11866701
Complement component C3 iRNA compositions and methods of use thereof
granted
Frequently asked questions
How many pharma patents expire in 2044?
1,766 published patents in our USPTO index have expiration dates falling in calendar year 2044.